Rituximab for Pediatric Renal Transplant Rejection

This study has been completed.
Sponsor:
Collaborator:
Genentech and Biogen IDEC
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00697996
First received: June 11, 2008
Last updated: December 19, 2008
Last verified: December 2008
  Purpose

Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University


Condition Intervention Phase
Kidney Transplantation
Drug: Rituximab for transplant rejection
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Open-Labeled Randomized Study of Rituximab Versus Standard of Care, for Treatment of Acute Allograft Rejection in Pediatric Renal Transplantation

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Rituximab safety in pediatric patients

Secondary Outcome Measures:
  • resolution fo graft rejection

Estimated Enrollment: 20
Study Start Date: June 2005
Estimated Study Completion Date: August 2007
Detailed Description:

Twenty kidney transplant recipients who are being cared for at Stanford University and UCLA and are between the ages of 2-21, can be considered for participation in this research if they are having an acute rejection episode. After a biopsy is done and the diagnosis of acute rejection is made, ten patients will be randomly enrolled in the group to be treated with Rituximab and steroid pulses. Ten children will be enrolled as the control group, receiving standard of care for acute transplant rejection.

Assignment will be based on a 1:1 randomization scheme. That means two patients will be assigned to the group of patients receiving steroid pulsing and 4 doses of Rituximab. The third patient would be assigned to the group receiving steroid pulses and adjustment in immunosuppression medications which is the standard of care at Stanford University.

The dose of Rituximab that will be given is 375 mg/m2 and is administered through an IV. Additional doses of Rituximab will be administered on a weekly basis. A total of four doses will be given.

If the acute rejection does not resolve by one-week, patients in both groups have the option of receiving polyclonal antibody therapy.

  Eligibility

Ages Eligible for Study:   5 Years to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Patients must meet the following inclusion criteria to be eligible for study entry:

  • Pediatric renal allograft recipients aged 2-21 years with biopsy proven acute rejection episodes.
  • Able and willing to give written informed consent and comply with the requirements of the study protocol (patients >18 years of age or parents)
  • Greater than 30% decline in baseline renal function as indicated by a rise in the serum creatinine.
  • Adequate liver function, as indicated by AST or ALT <2x upper limit of normal unless related to primary disease.
  • Negative serum pregnancy test (for women of child bearing age)
  • Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months (1 year) after completion of treatment.&#xA;

Exclusion Criteria:Patients will be excluded from the study based on the following criteria:

  • Treatment with any investigational agent within 4 weeks of screening or 5 half-lives of the investigational drug (whichever is longer)
  • Receipt of a live vaccine within 4 weeks prior to randomization
  • Previous Treatment with Rituximab (MabThera® / Rituxan®)
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • History of HIV (positive HIV, HIV conducted during screening if applicable)
  • History of Hepatitis B and/or Hepatitis C (Hep B/C at screening)
  • History of recurrent significant infection or history of recurrent bacterial infections
  • Known active bacterial, viral, fungal, mycobacterial, or other infection (including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening
  • Ongoing use of high dose steroids (>10mg/day) or unstable steroid dose in the past 4 weeks.
  • Lack of peripheral venous access
  • History of drug, alcohol, or chemical abuse within 6 months prior to screening
  • Pregnancy (a negative serum pregnancy test should be performed for all women of childbearing potential within 7 days of treatment) or lactation
  • Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
  • History of psychiatric disorder
  • Significant cardiac or pulmonary disease (including obstructive pulmonary disease)
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
  • Inability to comply with study and follow-up procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00697996

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Genentech and Biogen IDEC
Investigators
Principal Investigator: Minnie M. Sarwal Stanford University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00697996     History of Changes
Other Study ID Numbers: SU-06102008-1196
Study First Received: June 11, 2008
Last Updated: December 19, 2008
Health Authority: United States: Food and Drug Administration
USA:GENETECH AND BIOGEN IDEC

Additional relevant MeSH terms:
Rituximab
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents

ClinicalTrials.gov processed this record on August 19, 2014